RxDoctor Payments Data

Oriana Damas, MD

Gastroenterology · Miami, FLNPI 1710159090

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,672 of the $25,459 with a category attached, or 96.9%. 5 manufacturers reported payments, led by AbbVie at 39.3% of the total. 2025 is the largest year on record at $8,578, more than ten times the $15 reported in 2020. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,459in general payments, 2019–2025

Across 25 payments — averaging $1018.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$10K
  • Takeda Pharmaceuticals U.S.A., Inc.$10K
  • Janssen Scientific Affairs, LLC$5K
  • Johnson & Johnson$1K
  • Axonics, Inc.$15
$878,003in research payments, 2019–2025

Across 14 payments — averaging $62,715 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$787K
  • Amgen$63K
  • E.r. Squibb & Sons, L.L.C.$28K

What the payments were for

  • Consulting fees$24,67297%
  • Food & beverage$7873%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,459 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$19,099
Medicare patients
83
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab60$1,592,615
RinvoqUpadacitinib14$159,904
Humira(Cf) PenAdalimumab11$151,389
Mesalamine25$8,115
ClenpiqSod Picosulf/Mag Ox/Citric Ac18$3,109
Colestipol Hcl20$1,513
Balsalazide Disodium17$926
LoperamideLoperamide Hcl12$604
Pantoprazole Sodium15$317
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,156$1,592,61560 claims
AbbVieRinvoq$10,007$159,90414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →